Jill A. Howe - 05 Mar 2026 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: LCTX
Reported as of: 05 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Mar 2026, 19:50:33 UTC
Prior SEC filing: 12 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Jill A. Howe

Key filing fact

Jill A. Howe filed Form 4 for Lineage Cell Therapeutics, Inc. (LCTX) on 06 Mar 2026.

Key facts

This page summarizes Jill A. Howe's Form 4 filing for Lineage Cell Therapeutics, Inc. (LCTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Mar 2026, 19:50.

Change

Previous filing in this sequence was filed on 12 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001892397 Primary reporting owner

Howe Jill Ann

Relationship: Chief Financial Officer
Address: C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD
Signature: /s/ Jill A. Howe
Signature date: 06 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LCTX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,050,000
Change %
Price: $0.000000^*
Shares after: 1,050,000
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 1,050,000
Exercise price: $1.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.